Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737063 | 0.83 | TEAD4 (0.50) | P2RX3NPSR1HTT | |
| SCHEMBL509776 | 0.82 | LTA4H (0.50) | LTA4HMAOAGRM5HTT | |
| SCHEMBL11411731 | 0.82 | LTA4H (0.50) | NPSR1LTA4HHTTL3MBTL1 | |
| SCHEMBL14195600 | 0.81 | TGFBR1 (0.46) | GRM5 | |
| SCHEMBL11416270 | 0.80 | GRM5 (0.51) | GRM5HTT | |
| SCHEMBL20176873 | 0.80 | TGFBR1 (0.46) | LTA4H | |
| SCHEMBL751951 | 0.80 | MEN1 (0.44) | GRM5HTTL3MBTL1 | |
| SCHEMBL1446447 | 0.80 | MAP4K4 (0.41) | P2RX3GRM5 | |
| SCHEMBL4797810 | 0.80 | MAP4K4 (0.41) | P2RX3GRM5 | |
| SCHEMBL11415743 | 0.80 | MAPT (0.47) | P2RX3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-0317265-B1 | Novel imidate insecticides | ZENECA INC (US) | 1994-06-01 | — | — | EP | disclosed |
| US-5089623-A | Certain imidate insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-18 | — | — | US | disclosed |
| US-5070210-A | Novel ketenimines as intermediates for insecticides | ICI AMERICAS INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-5070097-A | MITICIDES | ICI AMERICAS INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-5064846-A | Heterocyclic insecticides | ICI AMERICAS INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-5045566-A | Phenyl or naphthyl substituted | ICI AMERICAS INC. (US) | 1991-09-03 | — | — | US | disclosed |
| US-4994473-A | For plants | ICI AMERICAS INC. (US) | 1991-02-19 | — | — | US | disclosed |
| US-4994488-A | Controlling Lepidoptera | ICI AMERICAS INC. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0317265-A2 | Novel imidate insecticides | ZENECA INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| EP-0317259-A2 | Heterocyclic insecticides | ICI AMERICAS INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| US-4229448-A | 5-Substituted picolinic acid derivatives and an anti-hypertensive composition containing the same | MEUJI SEIKA KAISHA LTD. (JP) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | P2RX3 207/4885NPSR1 922/4885LTA4H 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.